BlossomHill Therapeutics, Inc.

BlossomHill Therapeutics, Inc.

NNASDAQ:BLSM
13.65
USD
-0.37
(-2.64%)
-0.82EPS
Mar 03Next Earn

Important Dates

BlossomHill Therapeutics, Inc.'s next confirmed earnings release is scheduled for March 3, 2027.

Earnings Date3/3/2027

Share Statistics

As of June 30, 2026, BlossomHill Therapeutics, Inc. has 30.64M shares outstanding.

Shares Outstanding30.64M

Financial Position

As of June 30, 2026, BlossomHill Therapeutics, Inc. maintains a current ratio of 5.42, meaning it holds 5.4x the short-term assets needed to cover near-term liabilities.

Current Ratio5.42
Quick Ratio5.12
Debt / Equity-13.37

Financial Efficiency

These figures cover the twelve months ended June 30, 2026. The company generates approximately - - in revenue per employee across its workforce of 63.00, a quick read on workforce productivity versus industry peers.

Employee Count63.00

Stock Price Statistics

USD

These figures are as of the close on November 16, 2026.

50-Day Moving Average17.84

Income Statement

USD

These figures cover the twelve months ended June 30, 2026.

Pretax Income-23.76M

Balance Sheet

USD

As of June 30, 2026, BlossomHill Therapeutics, Inc. holds 95.38M in cash and equivalents against 23.37M in total debt, resulting in a net debt position of -95.38M. Total book value stands at -174.78M, with working capital of 82.35M providing operational flexibility.

Cash & Cash Equivalents95.38M
Total Debt23.37M
Net Debt-95.38M
Equity (Book Value)-174.78M
Book Value Per Share-5.70
Working Capital82.35M

Cash Flow

USD

These figures cover the twelve months ended June 30, 2026. After subtracting - - in capital expenditures, free cash flow totaled -23.23M - equivalent to -0.80 per share.

Free Cash Flow-23.23M
FCF Per Share-0.80